Study guide
1.4 Clinical Toxicology & Acute Poisoning
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
1.4 Clinical Toxicology & Acute Poisoning
Key Takeaways Explain This Topic AI
Paracetamol hepatotoxicity results from the depletion of hepatic glutathione by the reactive metabolite NAPQI; serum levels drawn at or after 4 hours guide N-acetylcysteine (NAC) therapy, but presentation >8 hours or staggered overdose requires immediate NAC without waiting for blood results.
The simplified SNAP (Scottish and Newcastle Acetylcysteine Protocol) 12-hour regimen (100 mg/kg over 2 hours, then 200 mg/kg over 10 hours) markedly reduces adverse anaphylactoid reactions compared to historical regimens.
Salicylate poisoning induces a characteristic mixed respiratory alkalosis and high anion gap metabolic acidosis; management centers on urinary alkalinisation with IV sodium bicarbonate and early haemodialysis for severe toxicity.
High-yield antidotes include naloxone for opioid respiratory depression, DigiFab for cardiac glycosides, glucagon for beta-blockers, fomepizole for toxic alcohols, and 100% normobaric/hyperbaric oxygen for carbon monoxide.
Last updated: October 2026
Clinical Toxicology & Acute Poisoning
Acute poisoning and intentional overdoses account for substantial emergency department admissions in the United Kingdom. Clinical management is guided by the National Poisons Information Service (NPIS) via TOXBASE , the British National Formulary (BNF) , and NICE clinical guidelines . The cornerstone of toxicology management is aggressive ABCDE supportive care followed by targeted antidotal therapy.
Paracetamol (Acetaminophen) Overdose
Paracetamol is the most common agent taken in deliberate self-harm in the UK. Understanding its metabolism and time-sensitive antidotal therapy is essential for preventing acute liver failure.
Pathophysiology of Hepatotoxicity
At therapeutic doses, >90% of paracetamol is metabolized by hepatic glucuronidation and sulfation into non-toxic conjugates. A minor fraction (~5–10%) is metabolized by cytochrome CYP2E1 to the highly reactive, electrophilic, and hepatotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) . NAPQI is normally detoxified by conjugation with endogenous hepatic glutathione into harmless mercapturic acid conjugates.
In overdose, normal sulfation and glucuronidation pathways become saturated. Excess paracetamol is shunted to CYP2E1, producing massive quantities of NAPQI. Once hepatic glutathione stores are depleted to <30% of normal , un-conjugated NAPQI binds covalently to intracellular hepatocyte proteins and mitochondrial structures, causing acute centrilobular hepatic necrosis and fulminant liver failure. [ Paracetamol Ingestion ]
- │
- ┌──────────────────────┴──────────────────────┐
- ▼ ▼
- [ Glucuronidation & Sulfation ] [ CYP2E1 Oxidation ]
- (Major pathways: saturated in OD) │
- │ ▼
- [ Non-Toxic Metabolites ] [ NAPQI ] (Toxic)
- │
- ┌─────────────────────────┴─────────────────────────┐
- ▼ ▼
- [ Normal / Low Ingestion ] [ Severe Overdose ]
- + Glutathione Conjugation Glutathione Depleted (<30%)
- │ │
- ▼ ▼
- [ Non-Toxic Mercapturate ] [ Covalent Protein Binding ]
- [ Centrilobular Necrosis ]
- [ Acute Liver Failure ]
- The UK Paracetamol Treatment Nomogram & Timings
Single Acute Ingestion < 4 Hours: Paracetamol absorption is ongoing. Blood paracetamol concentration drawn before 4 hours cannot be interpreted on the nomogram. Measure serum paracetamol, ALT, creatinine, and INR at 4 hours post-ingestion .
Single Acute Ingestion 4 to 8 Hours: Draw blood paracetamol concentration immediately. Await the result and compare to the single UK treatment line (starting at 100 mg/L at 4 hours). If on or above the line, start IV N-acetylcysteine (NAC) .
Presentation > 8 Hours Post-Ingestion: The efficacy of NAC decreases with delay, particularly beyond 8 hours. Commence IV NAC immediately without waiting for laboratory results. If the subsequent level is below the line and ALT/INR are normal, NAC may be discontinued.
Staggered Overdose (taken over >1 hour): The nomogram cannot be used. Commence IV NAC immediately regardless of time elapsed.
Simplified SNAP Regimen (12-Hour Protocol)
The Scottish and Newcastle Acetylcysteine Protocol (SNAP) is now used by many UK hospitals (follow the local protocol and TOXBASE; the licensed 21-hour three-bag regimen is still used elsewhere), delivering the total therapeutic dose of 300 mg/kg over 12 hours instead of 21 hours:
- Infusion Dose & Diluent Infusion Rate & Duration
- First Infusion 100 mg/kg in 200 mL 5% glucose (or 0.9% saline) Over 2 hours (50 mg/kg/hour)
- Second Infusion 200 mg/kg in 1000 mL 5% glucose (or 0.9% saline) Over 10 hours (20 mg/kg/hour)
Total Dose: 300 mg/kg over 12 hours.
End of Infusion Testing: Check ALT, INR, creatinine, and paracetamol level 2 hours before the second infusion finishes (at 10 hours). If ALT is normal, INR ≤1.3, and paracetamol is undetectable, stop NAC. Continue infusion (at 20 mg/kg/hour) if ALT is rising, INR >1.3, or paracetamol remains detectable.
Anaphylactoid Reactions: Non-IgE mediated histamine release (flushing, pruritus, wheeze) occurs in ~10–15% of patients, usually during the first infusion. Manage by temporarily stopping the infusion, giving an antihistamine ± salbutamol, and restarting once symptoms settle (per local protocol); these reactions are not true allergy and are not a reason to withhold acetylcysteine.
King's College Hospital Criteria for Acute Liver Failure
In paracetamol-induced acute liver failure, the King's College Hospital Criteria determine when emergency referral for super-urgent orthotopic liver transplantation is indicated:
Important
King's College Criteria (Paracetamol-Induced ALF): Emergency liver transplantation is indicated if:
Arterial pH < 7.30 (measured at 24 hours post-ingestion or following adequate fluid resuscitation), OR
All three of the following concurrent parameters are present:
- Prothrombin time > 100 seconds (or INR > 6.5 )
- Serum creatinine > 300 µmol/L (3.4 mg/dL)
- Grade III or IV hepatic encephalopathy (confusion/somnolence or coma)
- Opioid Toxicity & Naloxone Titration
Clinical Triad: CNS depression (coma), respiratory depression (bradypnoea <8–10 breaths/min), and pinpoint pupils (miosis).
Antidote: Naloxone is a competitive opioid mu-receptor antagonist.
Titration Goal: The objective of naloxone therapy is adequate spontaneous respiratory ventilation (respiratory rate >10–12 breaths/min), not complete restoration of consciousness. Abrupt reversal precipitates acute opioid withdrawal, severe agitation, vomiting, and non-cardiogenic pulmonary oedema.
Dosing (BNF, opioid overdose): Give 400 micrograms IV , then 800 micrograms for up to two doses at 1-minute intervals if there is no response, then 2 mg (4 mg may be needed in seriously poisoned patients); if there is still no response, reconsider the diagnosis. When respiratory depression must be reversed without precipitating withdrawal or pain (for example in palliative or postoperative patients), titrate smaller increments such as 100–200 micrograms.
Pharmacokinetics: Naloxone has a short half-life (30–90 minutes). Long-acting opioids (e.g., methadone, sustained-release oxycodone) will outlast naloxone; observe closely for rebound resedation and initiate an IV naloxone infusion if recurrent hypoventilation occurs.
Salicylate (Aspirin) Poisoning
Pathophysiology: Salicylates directly stimulate the medullary respiratory center, causing hyperventilation and a primary respiratory alkalosis . Simultaneously, salicylates uncouple mitochondrial oxidative phosphorylation, leading to anaerobic glycolysis, accumulation of lactic acid and ketoacids, and a primary high anion gap metabolic acidosis .
Classic Acid-Base Finding: Mixed respiratory alkalosis and metabolic acidosis .
Clinical Presentation: Tinnitus, vertigo, nausea, vomiting, diaphoresis, hyperpyrexia, tachypnoea, confusion, seizures, pulmonary oedema.
Management:
Activated Charcoal (50 g): If presenting within 1–2 hours of ingestion (repeat doses considered for large ingestions with bezoar formation).
Urinary Alkalinisation: Administer intravenous Sodium Bicarbonate (1.26% or 8.4%) with potassium chloride to maintain urine pH between 7.5 and 8.5 . Alkalinising the urine ionizes salicylic acid to salicylate, 'ion-trapping' it within the renal tubules and accelerating urinary excretion.
Haemodialysis Indications: Salicylate level >700 mg/L (5.1 mmol/L), severe refractory metabolic acidosis (pH <7.20), renal failure, pulmonary oedema, or progressive neurological deterioration (coma, seizures).
Carbon Monoxide (CO) Poisoning
Mechanism: CO binds haemoglobin with an affinity >200 times higher than oxygen, forming carboxyhaemoglobin (COHb) . This severely impairs oxygen-carrying capacity and shifts the oxyhaemoglobin dissociation curve to the left (inhibiting tissue oxygen release), while inhibiting cytochrome c oxidase.
Clinical Features: Headache, nausea, dizziness, lethargy, cognitive impairment, myocardial ischaemia, arrhythmias. Cherry-red skin is a rare post-mortem sign.
Diagnostic Trap: Standard pulse oximetry ( SpO2 ) cannot distinguish carboxyhaemoglobin from oxyhaemoglobin and reads falsely normal . Diagnosis requires venous or arterial blood gas co-oximetry measuring COHb percentage (>10% in smokers, >3% in non-smokers).
Treatment: Immediate 100% high-flow normobaric oxygen via non-rebreathe mask (reduces COHb half-life from 320 to 80 minutes). Hyperbaric oxygen (HBO) is discussed with TOXBASE or a hyperbaric unit for severe cases (for example loss of consciousness, neurological signs, myocardial ischaemia, pregnancy or very high COHb); evidence of benefit is mixed, so 100% normobaric oxygen remains the universal first step.
Core UK Clinical Antidotes Summary
Toxic Substance Mechanism of Toxicity Specific Antidote Mechanism of Antidote Action
Paracetamol Toxic NAPQI production & glutathione depletion N-acetylcysteine (NAC) Replenishes hepatic glutathione; acts as direct glutathione substitute
Opioids Mu-receptor agonism (respiratory arrest) Naloxone Competitive opioid receptor antagonist
Salicylates Oxidative phosphorylation uncoupling Sodium Bicarbonate Alkalinises urine (pH 7.5–8.5) to promote renal salicylate elimination
Carbon Monoxide Carboxyhaemoglobin formation 100% O2 / Hyperbaric O2 Displaces CO from haemoglobin and cytochrome enzymes
Beta-Blockers Bradycardia, hypotension, cardiogenic shock Glucagon (first-line); High-dose insulin (HIET) Stimulates myocardial adenylate cyclase independently of beta receptors
Digoxin Na+/K+ ATPase inhibition (hyperkalaemic arrhythmias) Digoxin-specific antibody fragments (DigiFab) Binds free intravascular digoxin, facilitating rapid renal clearance
Toxic Alcohols (Ethylene Glycol / Methanol) Toxic acid metabolites (oxalate / formic acid) causing visual loss and severe metabolic acidosis Fomepizole (or IV Ethanol) Inhibits alcohol dehydrogenase, preventing formation of toxic metabolites
Iron Free radical generation, corrosive GI ulceration, shock Desferrioxamine Chelates ferric iron into soluble ferrioxamine excreted in urine (vin rosé urine)
Cyanide Cytochrome c oxidase inhibition Hydroxocobalamin Binds cyanide to form non-toxic cyanocobalamin (Vitamin B12)